Zydus Cadila Q4 net up 46%; revenues jump 16%

Standalone net profit for Q4FY15 up 60%

Ahmedabad-based drug major Cadila Healthcare Ltd, has posted a net profit of Rs  350 crore for the quarter ended March 31, 2015 (Q4FY15) as compared to Rs  239.1 crore in the corresponding quarter last fiscal, up 46% on the back of a 16 per cent rise in total income from operations during the quarter, which stood at Rs  2308.5 crore as against Rs  1981 crore in the year-before period.

For the full year 2014-15, the Group has posted a net profit of Rs  1150.5 crore, up by 43 per cent from Rs  803.5 crore in 2013-14, on the back of a 19.6 per cent rise in total income. The total income from operations stood at Rs  8706.7 crore in Fy15, as against Rs  7274 crore in FY14.

On a standalone basis, however, the company has posted 60 per cent rise in net profit for the fourth quarter of fiscal 2014-15 to Rs  347 crore, up from Rs  216 crore in the year-before period. The total income during the quarter increased 31 per cent to touch Rs  1468.8 crore, up from Rs  1121.8 crore in the corresponding period last fiscal.

 

For the full year period, the company posted a net profit of Rs  1271 crore, up 40 per cent from Rs  903 crore in FY14, on the back of a 25 per cent rise in total income, which rose from Rs  4350 crore to Rs  5469 crore.

The Board of Directors of the company in their meeting proposed a dividend of  240 per cent.  

During the year, the group launched Exemptia, the world’s first biosimilar for Adalimumab, and has strong biologics pipeline under development in India.

Exemptia is marketed by Zydus Biovation and Zydus BioNext, new divisions launched exclusively to market this therapy for inflammatory arthritis and inflammatory bowel disease. During the year, the group also launched SoviHep, therapy for Hepatitis C in alliance with Gilead Sciences.

The group has been exploring newer treatment options for its breakthrough drug Lipaglyn (Saroglitazar) and initiated Phase III trials of the molecule for patients suffering from lipodystrophy and nonalcoholic steatohepatitis (NASH), during the year. The group also initiated Phase I clinical trials in the US for ZYDPLA1, a novel, orally active, small molecule DPP-4 inhibitor to treat Type-2 Diabetes. Phase I clinical trials are also underway in Australia for its IND - ZYAN 1, a HIF-PH inhibitor for treating anemia.

The group filed 38 ANDAs during the year with the USFDA, taking the cumulative filings to 260, and received eight ANDA approvals during the year taking the total to 99 product approvals.